
Forbion is a global life sciences venture capital firm headquartered in Naarden, the Netherlands, with additional offices in Munich and Boston. The firm manages around 5 billion euros across multiple fund strategies spanning the full lifecycle of biopharmaceutical innovation. In addition to its longstanding human health focus, Forbion also invests in planetary health solutions through its BioEconomy strategy. The BioEconomy Fund I was created to support biotechnologies and green chemistries that can scale industrial sustainability across food, agriculture, materials and environmental technologies.
Forbion BioEconomy Fund I invests in companies leveraging biotechnology for planetary health, particularly innovations that clean, feed and restore the planet. The fund focuses on early and growth-stage companies in foodtech, agritech, biomaterials and environmental biotechnology, with an emphasis on scalable industrial applications. Its goal is to back technologies that drive measurable environmental impact while enabling commercial viability.
Forbion has closed its BioEconomy Fund I at 200 million euros. Launched in 2024, this vehicle is designed to support companies across four core verticals: food, agriculture, materials and environmental technologies.
The fund is backed by a strong consortium of European and North American institutional investors, including KfW Capital, Novo Holdings, Rentenbank, Aurae Impact, ABN AMRO Bank and EIFO. The fund expands Forbion’s planetary health strategy by targeting biotechnologies and green chemistries that enhance industrial sustainability at scale.
It aims to invest in a portfolio of innovators developing biologically driven solutions for carbon reduction, regenerative inputs, new materials and industrial environmental technologies.
Leadership
The BioEconomy Fund I is led by general partners Alexander Hoffmann and Joy Faucher, supported by Forbion’s broader global investment team of over 30 professionals. The leadership team brings deep sector expertise across biotechnology, industrial processes, green chemistry, biomanufacturing and venture scaling.
Investment Strategy
The fund’s strategy centers on identifying and backing biotechnology platforms that can transform industrial systems. This includes leveraging biological processes for sustainable food production, next-generation agriculture inputs, alternative proteins, soil and nutrient technologies, biomaterials and environmental remediation. Forbion employs a hands-on approach, combining scientific diligence, commercial guidance and long-term capital support. Its global footprint and strong LP base provide portfolio companies with access to scientific networks, industrial partners and downstream capital across Europe and North America.
Notable Investments
The BioEconomy Fund I portfolio includes companies such as:
These companies are developing novel biomaterials, agricultural biotech platforms, climate-positive food systems and environmentally focused biological technologies. Collectively, they reflect Forbion’s thesis that biotechnology can serve as a foundation for scalable industrial sustainability.
Notable Exits
As a recently launched fund, Forbion BioEconomy Fund I has not yet reported notable exits. Forbion’s broader history across 11 funds and more than 130 portfolio companies includes multiple approved therapies and successful exits in biotech and life sciences.
Other
Forbion brings a dual advantage: deep biotech expertise and a global platform that bridges both human health and planetary health. The BioEconomy Fund I is well-positioned for startups seeking partners with scientific depth, regulatory experience, industrial understanding and international investor networks.
The fund’s LP base includes major European institutional investors whose missions align closely with sustainability and industrial transformation, offering strategic relationships beyond capital.
For companies developing biotechnological solutions for food, agriculture, materials or environmental systems, Forbion offers both scale and technical sophistication.
Netherlands